{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:40:23Z","timestamp":1793706023518,"version":"4.6.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["534961357"],"award-info":[{"award-number":["534961357"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T18:54:58Z","timestamp":1750359298000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Epigenetic dysregulation in acute myeloid leukemia"],"prefix":"10.1053","volume":"62","author":[{"given":"Jens","family":"Schrezenmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.P.","family":"Huntly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.06.003_bib0001","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0002","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0003","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41588-023-01471-2","article-title":"In vivo screening characterizes chromatin factor functions during normal and malignant hematopoiesis","volume":"55","author":"Lara-Astiaso","year":"2023","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0004","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1101\/gr.269233.120","article-title":"DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia","volume":"31","author":"Giacopelli","year":"2021","journal-title":"Genome Res"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0005","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-020-15221-z","article-title":"Chromatin accessibility promotes hematopoietic and leukemia stem cell activity","volume":"11","author":"Cabal-Hierro","year":"2020","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114498","article-title":"STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia","volume":"43","author":"Fischer","year":"2024","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0007","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.2019001553","article-title":"Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies","volume":"134","author":"Sasca","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0008","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature24678","article-title":"Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control","volume":"552","author":"Barbieri","year":"2017","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0009","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/2159-8290.CD-22-0210","article-title":"A dynamic rRNA ribomethylome drives stemness in acute myeloid leukemia","volume":"13","author":"Zhou","year":"2023","journal-title":"Cancer Discovery"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/890","article-title":"Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases","volume":"19","author":"Okano","year":"1998","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0013","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0014","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.leu.2404611","article-title":"Discovery of epigenetically silenced genes in acute myeloid leukemias","volume":"21","author":"Desmond","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.cell.2017.01.021","article-title":"CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression","volume":"168","author":"Spencer","year":"2017","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0016","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0017","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0018","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41467-024-55691-z","article-title":"Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication","volume":"16","author":"Lee","year":"2025","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0019","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41588-022-01179-9","article-title":"Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation","volume":"54","author":"Nam","year":"2022","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2018.03.025","article-title":"Loss of Dnmt3a immortalizes hematopoietic stem cells In vivo","volume":"23","author":"Jeong","year":"2018","journal-title":"Cell Reports"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0021","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1074\/jbc.RA118.006795","article-title":"Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners","volume":"294","author":"Sandoval","year":"2019","journal-title":"Journal of Biological Chemistry"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/leu.2017.200","article-title":"German-austrian Acute Myeloid Leukemia Study Group (AMLSG), DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia","volume":"32","author":"Gaidzik","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0023","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukemic hematopoietic stem cells in acute leukemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0024","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/2159-8290.CD-21-0560","article-title":"Systematic profiling of DNMT3A variants reveals protein instability mediated by the DCAF8 E3 ubiquitin ligase adaptor","volume":"12","author":"Huang","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0025","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0027","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1038\/s41467-021-26093-2","article-title":"TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis","volume":"12","author":"Tulstrup","year":"2021","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0028","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41586-024-07969-x","article-title":"RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis","volume":"634","author":"Zou","year":"2024","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0029","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0030","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0031","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0032","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0033","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature24294","article-title":"BCAT1 restricts \u03b1kg levels in AML stem cells leading to IDHmut-like DNA hypermethylation","volume":"551","author":"Raffel","year":"2017","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0034","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","author":"DiNardo","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0036","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0037","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0038","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/leu.2017.213","article-title":"The MLL recombinome of acute leukemias in 2017","volume":"32","author":"Meyer","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0039","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","article-title":"AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia","volume":"37","author":"Lin","year":"2010","journal-title":"Mol Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0041","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0042","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.celrep.2019.01.058","article-title":"Structural basis for recognition of ubiquitylated nucleosome by Dot1L methyltransferase","volume":"26","author":"Anderson","year":"2019","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0043","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9\u2013mediated leukemogenesis","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0044","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0503072102","article-title":"Global and hox-specific roles for the MLL1 methyltransferase","volume":"102","author":"Guenther","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0045","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0046","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The Menin Tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0047","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1158\/0008-5472.CAN-13-3602","article-title":"Validation and structural characterization of the LEDGF\/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia","volume":"74","author":"Cerm\u00e1kov\u00e1","year":"2014","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0048","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0049","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0050","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0051","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0052","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0053","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"JCO"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0054","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"The Lancet Oncology"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0055","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discovery"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0056","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0057","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0058","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1158\/2159-8290.CD-23-0876","article-title":"Condensate-promoting ENL mutation drives tumorigenesis In vivo through dynamic regulation of histone modifications and gene expression","volume":"14","author":"Liu","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0059","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood.2023021234","article-title":"Transcriptional control of leukemogenesis by the chromatin reader SGF29","volume":"143","author":"Barbosa","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ydbio.2009.10.004","article-title":"Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice","volume":"337","author":"Fisher","year":"2010","journal-title":"Dev Biol"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0061","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1172\/JCI70739","article-title":"Myelodysplastic syndromes are induced by histone methylation\u2013altering ASXL1 mutations","volume":"123","author":"Inoue","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0062","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0063","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0064","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/s41467-018-05085-9","article-title":"Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis","volume":"9","author":"Asada","year":"2018","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-024-01590-1","article-title":"Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients","volume":"17","author":"Halik","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0066","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.3324\/haematol.2019.222323","article-title":"EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia","volume":"105","author":"Stasik","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0067","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0068","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nm.4247","article-title":"Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia","volume":"23","author":"G\u00f6llner","year":"2017","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0069","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41588-018-0114-z","article-title":"UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs","volume":"50","author":"Gozdecka","year":"2018","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0070","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the functional output of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0071","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/onc.2015.92","article-title":"The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia","volume":"35","author":"Giotopoulos","year":"2016","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0072","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood.2022019306","article-title":"Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation","volume":"145","author":"Shah","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0073","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/2159-8290.CD-20-1459","article-title":"KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene expression programs","volume":"12","author":"Yan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0074","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51754","article-title":"Loss of Kat2a enhances transcriptional noise and depletes acute myeloid leukemia stem-like cells","volume":"9","author":"Domingues","year":"2020","journal-title":"Elife"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0075","doi-asserted-by":"crossref","first-page":"30673","DOI":"10.1074\/jbc.M109.042242","article-title":"Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors*","volume":"284","author":"Wada","year":"2009","journal-title":"Journal of Biological Chemistry"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0076","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0077","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3324\/haematol.2017.172411","article-title":"Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials","volume":"103","author":"Schlenk","year":"2018","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0078","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/ng.2731","article-title":"Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms","volume":"45","author":"Kon","year":"2013","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0079","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142149","article-title":"Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS\/AML","volume":"6","author":"Tothova","year":"2021","journal-title":"JCI Insight"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0080","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1101\/gad.301036.117","article-title":"m6A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover","volume":"31","author":"Ke","year":"2017","journal-title":"Genes Dev"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0081","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nchembio.687","article-title":"N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO","volume":"7","author":"Jia","year":"2011","journal-title":"Nat Chem Biol"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0082","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","article-title":"ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility","volume":"49","author":"Zheng","year":"2013","journal-title":"Mol Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0083","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0084","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.stem.2019.03.021","article-title":"Targeting the RNA m6A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia","volume":"25","author":"Paris","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0085","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/s41375-024-02358-9","article-title":"Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic and functional properties","volume":"38","author":"Boutzen","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0086","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41588-021-00941-9","article-title":"Automated CUT&tag profiling of chromatin heterogeneity in mixed-lineage leukemia","volume":"53","author":"Janssens","year":"2021","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.06.003_bib0087","article-title":"Long-read epigenomic diagnosis and prognosis of Acute myeloid leukemia","author":"Lamba","year":"2024","journal-title":"Res Sq"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:28:35Z","timestamp":1765632515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000289"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic dysregulation in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}